Alnylam Pharmaceuticals Inc (ALNY) reports robust revenue growth and promising clinical developments in the first quarter of 2024.
Omnicell Inc reports robust Q1 2024 results, driven by successful product launches and effective cost management.
Amidst revised upward financial forecasts and strong enrollment growth, LAUR navigates mixed market conditions with strategic finesse.